DeSilvey DL
FACC, FACP, Associate Professor, Cardiovascular Division, University of Virginia Health Science Center, Charlottesville, Virginia, USA.
J Thromb Thrombolysis. 1998 Nov;6(3):183-197. doi: 10.1023/A:1008878628326.
This article begins by discussing the pathogenesis of acute ischemic syndromes reviewing the cascade of ischemic events. We then go on to discuss the interventional management of acute ischemic syndromes and the benefits of early conservative therapy versus aggressive management with either PTCA or stenting. A discussion is then held regarding the pharmacological management of acute ischemic syndromes including the various agents involved including thrombolytic agents, aspirin, heparin and other measures. The main body of the article reviews the role of the 2B/3A inhibitors and the management of acute ischemic syndromes, including those studies that have been conducted to date, reviewing the role of the 2B/3A inhibitors and acute ischemic syndromes and the outcome from their application.
本文开篇讨论急性缺血综合征的发病机制,回顾缺血事件的一系列过程。接着我们继续探讨急性缺血综合征的介入治疗以及早期保守治疗与采用经皮冠状动脉腔内血管成形术(PTCA)或支架置入术的积极治疗相比的益处。然后讨论急性缺血综合征的药物治疗,包括所涉及的各种药物,如溶栓剂、阿司匹林、肝素及其他措施。文章主体部分回顾了2B/3A抑制剂的作用以及急性缺血综合征的治疗,包括迄今为止所开展的那些研究,审视2B/3A抑制剂在急性缺血综合征中的作用及其应用结果。